Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) rose 2.8% on Tuesday . The company traded as high as $46.89 and last traded at $46.41, with a volume of 205,241 shares changing hands. The stock had previously closed at $45.15.

Several brokerages recently weighed in on FPRX. Jefferies Group set a $60.00 price objective on Five Prime Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 5th. Leerink Swann restated a “buy” rating and set a $45.00 price objective on shares of Five Prime Therapeutics in a research report on Friday, July 15th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a report on Tuesday, July 12th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $48.00 target price on shares of Five Prime Therapeutics in a report on Thursday, May 19th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Five Prime Therapeutics presently has an average rating of “Buy” and a consensus price target of $52.33.

The company has a market cap of $1.25 billion and a P/E ratio of 5.20. The firm’s 50-day moving average price is $47.09 and its 200-day moving average price is $42.25.

Five Prime Therapeutics (NASDAQ:FPRX) last released its earnings results on Thursday, August 4th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.07. The company earned $9.23 million during the quarter, compared to the consensus estimate of $6.38 million. The company’s revenue was up 46.1% on a year-over-year basis. During the same period last year, the firm posted ($0.45) EPS. Equities research analysts forecast that Five Prime Therapeutics Inc. will post ($2.37) EPS for the current fiscal year.

In other news, Director William R. Ringo sold 500 shares of the business’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $50.77, for a total value of $25,385.00. Following the completion of the sale, the director now owns 500 shares of the company’s stock, valued at approximately $25,385. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Peder Jensen sold 12,195 shares of the business’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total value of $603,652.50. Following the completion of the sale, the director now directly owns 12,195 shares of the company’s stock, valued at approximately $603,652.50. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Five Prime Therapeutics stock. Schwab Charles Investment Management Inc. increased its position in shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) by 27.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,500 shares of the company’s stock after buying an additional 9,200 shares during the period. Schwab Charles Investment Management Inc. owned about 0.15% of Five Prime Therapeutics worth $1,764,000 as of its most recent filing with the SEC.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.